NOTCH1 and neoplasm: Recently, we reported that Crenigacestat, a gamma secretase inhibitor, targets the NOTCH1/DLL4/VEGFA/MMP13 axis, reducing iCCA progression in a patient-derived xenograft (PDX) model by blocking tumor neovascularization [20].